Grifols

Grifols FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Grifols (GRF.MC) as of Sep 17, 2026 is 155.27 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 426.73 % — a change of -63.62% (lower).

FCF Conversion

155.27 %

YoY

-63.62%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Grifols is 2026 155.27 % . FCF Conversion Rate (FCF/EBITDA) of Grifols was 2025 426.73 % . It decreases by -63.62% lower compared to the previous year.

The Grifols FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
72.02 EUR
Jan 1, 2019
25.05 EUR
Jan 1, 2020
120.89 EUR
Jan 1, 2021
106.24 EUR
Jan 1, 2022
-185.53 EUR
Jan 1, 2023
-146.91 EUR
Jan 1, 2024
426.73 EUR
Jan 1, 2025
155.27 EUR
The Grifols FCF Conversion history
YEARFCF ConversionYoY
155.27 %-63.62%
426.73 %-390.48%
-146.91 %-20.82%
-185.53 %-274.63%
106.24 %-12.12%
120.89 %+382.52%
25.05 %-65.21%
72.02 %-8.00%
78.28 %+63.86%
47.77 %+44.65%
33.03 %-77.55%
147.13 %
Access this data via the Eulerpool API

Grifols Stock analysis

What does Grifols do? Grifols SA is a globally operating company specialized in the manufacture and marketing of medical products and technologies. The company is headquartered in Barcelona, Spain and has been in existence for over 75 years. Grifols focuses on improving the quality of life through the production and marketing of blood products and services, diagnostics, and hospital pharmaceuticals. It has four main business areas: Bioscience, Hospital, Diagnostic, and Bio Supplies. Grifols emphasizes research and development to meet customer needs. It has introduced various products, including AlfaBIO, Vistogard, ID Core XT, NEO Blood Bank, and MIRASOL Pathogen Reduction Technology. Grifols is committed to innovation and quality, providing products and services that cater to a wide range of customers. Additionally, it is a significant employer in the biotechnology industry and contributes to economic development in different regions. Grifols is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grifols stock

FCF Conversion Rate (FCF/EBITDA) of Grifols is 155.27 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Grifols changed from 426.73 % to 155.27 %, representing a -63.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Grifols since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Grifols with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Grifols

All Key Metrics — Grifols